CER Daily Newsfeed

Value Viewpoint: Prying Open the Pharmacy Benefit Manager Black Box to Decode the 2026 PBM Reforms

(4/8, Kimberly Westrich, Kenneth Finegold, Roswell Cole, The Evidence Base) comments “...The flurry of activity in early 2026 marks the beginning, not the end, of PBM reform. For decades, the ‘black box’ of PBM operations added complexity to the pharmaceutical supply chain, but the combination of the CAA, the DOL's transparency mandates, and FTC enforcement may finally pry that box open. ‘Success will not be measured by the passage of laws, but by whether there is a tangible shift in the healthcare economy: lower out-of-pocket costs for patients, greater sustainability for independent pharmacies, and transparency for employers and taxpayers to ensure drug spending benefits patients rather than middleman profits.’” Full

Infographic – Target Practice: Making Real-World Evidence Credible Through the Target Trial Framework

(4/8, The Evidence Base) reports “...This infographic explores how the TTF brings rigor and transparency to observational research, enabling real-world data to be used to answer causal questions with increased credibility. It outlines the core principles of the framework, highlights where it can be applied across the product lifecycle and provides practical guidance on how to implement it effectively in RWE generation.” Full

Real-World Evidence Confirms Tafasitamab Benefit in R/R DLBCL

(4/8, Yan Leyfman, MD, Cancer Network) reports “...Saverno et al. demonstrate that tafasitamab/lenalidomide delivers meaningful clinical benefit across a diverse, community-based R/R DLBCL population—and that earlier use represents the most actionable lever to improve survival. The implication is straightforward but important: tafasitamab should be considered early, not late, in the treatment course of transplant-ineligible patients.” Full